("Scott+Scott†), an international securities and consumer rights litigation firm, today announced that it has filed a class action lawsuit against Defendants PomDoctor Ltd., Zhenyang Shi, Li Xu, Cogency Global, Joseph Stone Capital, LLC, and Marcum Asia CPAs, LLP (collectively, the "Defendants†). The action, which was filed in the U.S. District Court for the Southern District of New York and captioned Louie v. PomDoctor Ltd. et al., Ca. NEW YORK--(BUSINESS WIRE)---- $POM #POM--Scott+Scott Attorneys at L ...

Core Viewpoint - Scott+Scott Attorneys at Law LLP has filed a class action lawsuit against Picard Medical Inc. and several associated defendants, alleging violations of the Securities Exchange Act due to misleading statements and a fraudulent stock promotion scheme that led to significant losses for investors [1][3]. Group 1: Lawsuit Details - The lawsuit is filed in the U.S. District Court for the Northern District of California under the case name Louie v. Picard Medical, Inc. et al., with a lead plaintiff deadline set for April 3, 2026 [1][5]. - The class action targets individuals and entities that purchased Picard Medical Securities (PMI) between September 2, 2025, and October 31, 2025, who suffered damages as a result [1][4]. Group 2: Allegations Against Defendants - The complaint alleges that the defendants made materially false and misleading statements and failed to disclose adverse facts about Picard Medical's business and operations [3]. - It is claimed that the defendants orchestrated a "pump-and-dump" scheme, where the stock price was artificially inflated through a social media promotion involving impersonators posing as legitimate financial advisors [2][3]. Group 3: Company Overview - Picard Medical is involved in the design, manufacturing, and sale of medical devices, with its flagship product being the artificial heart "SynCardia TAH" [2]. - The company is headquartered in Tucson, Arizona, and operates in the United States, Europe, and China [2].

Core Viewpoint - Scott+Scott Attorneys at Law LLP is investigating potential misleading statements and omissions by Beta Bionics, Inc. that may have violated federal securities laws, following a significant drop in the company's stock price after disappointing financial results were announced [1][3]. Company Overview - Beta Bionics is a medical device company focused on designing, developing, and commercializing solutions for individuals with diabetes who require insulin [2]. Financial Performance - On January 8, 2026, Beta Bionics reported preliminary, unaudited topline financial results for Q4 2025, indicating at least 5,581 new patient starts, which fell short of the consensus expectation of 6,078 [3]. - Following the announcement, Beta Bionics' stock price decreased by approximately $11.85, or 37%, closing at $20.14 on January 9, 2026 [3].

NEW YORK--(BUSINESS WIRE)---- $MCTA #CharmingMedical--Scott+Scott Attorneys at Law LLP ("Scott+Scott†), an international securities and consumer rights litigation firm, today announced that it has filed a class action lawsuit against Defendants Charming Medical, Limited; Kit Wong; Ching Man Cheung; Josephine Yan Yeung; Leut Ming Gung; Shu Tai Victor Yu; Cathay Securities Inc.; WWC, P.C.; And Cogency Global, Inc. (collectively, the "Defendants†). The action, which was filed in the U.S. District Court for ...

Core Viewpoint - Scott+Scott Attorneys at Law LLP is investigating potential breaches of fiduciary duties by the directors of Green Dot Corporation in relation to a buyout by CommerceOne Financial Corporation and Smith Ventures, citing concerns over inadequate consideration for shareholders [1]. Group 1 - The investigation focuses on whether the buyout approved by Green Dot's directors was in the best interest of the shareholders [1]. - The buyout involves CommerceOne Financial Corporation and Smith Ventures, LLC, raising questions about the valuation and terms of the deal [1].

NEW YORK--(BUSINESS WIRE)---- $JYD #investigation--Scott+Scott Attorneys at Law LLP ("Scott+Scott†), an international securities and consumer rights litigation firm, today announced that it has filed a class action lawsuit against Defendants Jayud Global Logistics Limited, Xiaogang Geng, Alan Tan Khim Guan, Lin Bao, Mengmeng Hu, Freidman, LLP, and Marcum Asia CPAs, LLP (collectively, the ). The action, which was filed in the U.S. District Court for the Southern District of New "Defendants†York and capti ...

Core Viewpoint - Scott+Scott Attorneys at Law LLP is investigating Stride, Inc. for potentially issuing misleading statements and failing to disclose material information to investors, which may violate federal securities laws [1][3]. Company Overview - Stride, Inc. is an education management organization that offers online education as an alternative to traditional education for public school students, along with career learning programs [2]. Financial Performance - On October 28, 2025, Stride reported a financial outlook for fiscal year 2026 that did not meet analysts' expectations, citing issues with an upgraded online platform and a poor customer experience leading to higher withdrawal and lower conversion rates [3]. - Following the disappointing financial outlook, Stride's stock price plummeted by 54%, closing at $70.05 per share on October 29, 2025 [4].

Core Viewpoint - Scott+Scott Attorneys at Law LLP is investigating Fiserv, Inc. for potentially issuing misleading statements and failing to disclose material information to investors, which may violate federal securities laws [1][3]. Company Performance - Fiserv reported third-quarter earnings on October 29, 2025, with adjusted earnings of $2.04 per share, which fell short of analysts' expectations of $2.64 per share [3]. - The company revised its 2025 adjusted earnings forecast to a range of $8.50 to $8.60 per share, down from the previous forecast of $10.15 to $10.30 per share made in July 2025 [3]. - Following the earnings report, Fiserv's share price dropped significantly, reaching as low as $66.58 per share, a decline of approximately 47% from $126.17 per share on October 28, 2025, amid heavy trading volume [3]. Legal Investigation - The investigation by Scott+Scott focuses on whether Fiserv or its officers and directors misled investors or failed to disclose critical information [1]. - The firm specializes in representing clients harmed by securities law violations and has a strong track record in achieving significant settlements [5].

Core Points - Scott+Scott Attorneys at Law LLP is investigating Alvotech for potentially issuing misleading statements and failing to disclose material information to investors, which may violate federal securities laws [1] - Alvotech develops and manufactures biosimilar medicines, focusing on therapeutic areas such as autoimmune, eye, bone disorders, and cancer [2] - On November 2, 2025, Alvotech received a complete response letter (CRL) from the FDA regarding its Biologics License Application (BLA) for AVT05, a biosimilar candidate to Simponi®, indicating deficiencies that must be resolved before approval [3] - Following the FDA's announcement, Alvotech's stock price dropped approximately 34%, closing at $5.03 on November 3, 2025 [3]

Core Insights - Scott+Scott Attorneys at Law LLP is investigating Alvotech for potentially issuing misleading statements and failing to disclose material information to investors, which may violate federal securities laws [1][3] - Alvotech develops and manufactures biosimilar medicines, focusing on therapeutic areas such as autoimmune, eye, bone disorders, and cancer [2] - On November 2, 2025, Alvotech received a complete response letter (CRL) from the FDA regarding its Biologics License Application (BLA) for AVT05, a biosimilar candidate to Simponi®, indicating deficiencies that must be resolved before approval [3] - Following the FDA's announcement, Alvotech's stock price dropped approximately 34%, closing at $5.03 on November 3, 2025 [3]